Welireg

Active Ingredient(s): Belzutifan
FDA Approved: * August 13, 2021
Pharm Company: * MERCK SHARP DOHME
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Welireg Overview

Belzutifan, sold under the brand name Welireg, is a medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma.[1][2][3][4][5][6] It is taken by mouth.[1] The most common side effects include decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.[2] Belzutifan is an hy...

Read more Welireg Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Belzutifan

Recent Welireg Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Belzutifan
  • Tablet: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Welireg: (1 result)

Sorted by National Drug Code
  • 0006-5331 Welireg 40 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.

Other drugs which contain Belzutifan or a similar ingredient: (1 result)